reports
Dicerna Pharmaceuticals Inc: 1 director
A director at Dicerna Pharmaceuticals Inc sold 21,250 shares at 21.060USD and the significance rating of the trade was 85/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
ields Testing Support Ahead Of FOMC Meeting We continue to see signs of improving risk appetites alongside healthy market dynamics. As a result, our outlook remains constructive. A breakout to new highs in the Russell 2000 (IWM) and Russell Micro-Caps (IWC), above $234.50 and $159, would likely cause us to shift to an outright bullish stance. Small- & Micro-Caps. The Russell 2000 (IWM) and Russell Micro-Caps (IWC) are testing key resistance at $234.50 and $159, respectively. Sustained breakout...
VRNS VARONIS SYSTEMS INC.
REGN REGENERON PHARMACEUTICALS INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
NTAP NETAPP INC.
HSKA HESKA CORPORATION
FRPT FRESHPET INC
FATE FATE THERAPEUTICS INC
DRNA DICERNA PHARMACEUTICALS
CVLT COMMVAULT SYSTEMS INC.
BOX BOX INC. CLASS A
AGS ALLGEMEINE GOLD- UND SILBERSCHEIDEANSTALT AG
SGMS SCIENTIFIC GAMES CORPORATION
NTNX NUTANIX INC. CLASS A
NTLA INTELLIA THERAPEUTICS INC.
RHHBY ROCHE HOLDING AG ADS
DBX DROPBOX INC. CLASS A
BEAM BEAM THERAPEUTICS
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Bullish Outlook Intact; Mild Concerns Subside The action we are seeing in broad indexes, Sectors, and in market dynamics continues to support our overall bullish outlook. Additionally, the mild deterioration in market dynamics that we discussed the past two weeks is now much less of a concern. Continue to buy dips. · S&P 500. The major averages are hitting new all-time highs; and new highs are bullish. Key support levels we are watching on the S&P 500 include short-term support at 3870...
VNOM VIPER ENERGY PARTNERS LP
SM SM ENERGY COMPANY
RRC RANGE RESOURCES CORPORATION
PCRX PACIRA BIOSCIENCES INC.
MYGN MYRIAD GENETICS INC.
MTDR MATADOR RESOURCES COMPANY
LGND LIGAND PHARMACEUTICALS INCORPORATED
LE LANDS' END INC.
ITCI INTRA-CELLULAR THERAPIES INC.
INSM INSMED INCORPORATED
HALO HALOZYME THERAPEUTICS INC.
EDIT EDITAS MEDICINE INC.
EBS EMERGENT BIOSOLUTIONS INC.
DRNA DICERNA PHARMACEUTICALS
OXM OXFORD INDUSTRIES INC.
WTI W&T OFFSHORE INC.
BSM BLACK STONE MINERALS LP
NTLA INTELLIA THERAPEUTICS INC.
GOOS CANADA GOOSE HOLDINGS INC.
DMLP DORCHESTER MINERALS L.P.
IOVA IOVANCE BIOTHERAPEUTICS INC
LPI LAREDO PETROLEUM INC.
CPE CALLON PETROLEUM
GII SPDR S&P GLOBAL INFRASTRUCTURE
TVTX TRAVERE THERAPEUTICS INC
OXMU PRIME US REIT
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XONE EXONE CO
VKTX VIKING THERAPEUTICS
VIVO MERIDIAN BIOSCIENCE INC.
SMED SHARPS COMPLIANCE
SM SM ENERGY COMPANY
QADA QAD CLASS A
PERI PERION NETWORK LTD
ENLV ENLIVEX THERAPEUTICS
NK NANTKWEST
KRNT KORNIT DIGITAL LTD.
ICAD ICAD INC.
FCX FREEPORT-MCMORAN INC.
DRNA DICERNA PHARMACEUTICALS
DDD 3D SYSTEMS CORPORATION
CPST CAPSTONE TURBINE CORP.
CLVS CLOVIS ONCOLOGY INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
APPS DIGITAL TURBINE
ATKR ATKORE INC
ZIXI ZIX CORP.
MSON MISONIX INC.
AP AMPCO-PITTSBURGH
PLSE PULSE BIOSCIENCES
FLGT FULGENT GENETICS
PUMP PROPETRO HOLDING CORP.
VREX VAREX IMAGING CORPORATION
EXPI EXP WORLD HOLDINGS
URGN UROGEN PHARMA
RFL RAFAEL HOLDINGS CL B
FLNT FLUENT INC
STIM NEURONETICS
INS INSTONE REAL ESTATE GROUP AG
TBIO TRANSLATE BIO
ORGO ORGANOGENESIS HOLDINGS (A)
DT DYNATRACE INC.
AXLA AXCELLA HEALTH
SWTX SPRINGWORKS THERAPEUTICS
OCGN OCUGEN INC
XGN EXAGEN
DMTK DERMTECH INC
RVMD REVOLUTION MEDICINES
VRM VROOM
CPE CALLON PETROLEUM
BILL BILL.COM HOLDINGS
BEAM BEAM THERAPEUTICS
AMTI APPLIED MOLECULAR TRANSPORT
DNMR DANIMER SCIENTIFIC
PUBM INC.
RUBY PUBMATIC
RBC U.S. BANKS YIELD INDEX ETF
- Dave Nicoski
- Ross LaDuke
AMGN AMGEN INC.
SHOP SHOPIFY INC.
INCY INCYTE CORP
NEM NEWMONT CORPORATION
VEEV VEEVA SYSTEMS INC CLASS A
VRSN VERISIGN INC.
TSLA TESLA INC
REGN REGENERON PHARMACEUTICALS INC.
QTS QTS REALTY TRUST INC. CLASS A
NVDA NVIDIA CORPORATION
NDAQ NASDAQ INC.
MPWR MONOLITHIC POWER SYSTEMS INC.
MOH MOLINA HEALTHCARE INC.
MKTX MARKETAXESS HOLDINGS INC.
IPHI INPHI CORPORATION
HUM HUMANA INC.
FOLD AMICUS THERAPEUTICS INC.
EQT EQT CORPORATION
ELMD ELECTROMED
DRNA DICERNA PHARMACEUTICALS
DG DOLLAR GENERAL CORPORATION
CYTK CYTOKINETICS INCORPORATED
CNC CENTENE CORPORATION
CIO CITY OFFICE REIT INC.
ALXN ALEXION PHARMACEUTICALS INC.
ALNY ALNYLAM PHARMACEUTICALS INC
ACAD ACADIA PHARMACEUTICALS INC.
ABX. BARRICK GOLD CORPORATION
FIVN FIVE9 INC.
CCO. CAMECO CORPORATION
AYA. THE STARS GROUP
DSPG DSP GROUP INC.
LMT
PETS LOCKHEED MARTIN CORPORATION
WERN PETMED EXPRESS INC.
UTHR WERNER ENTERPRISES INC.
SBAC UNITED THERAPEUTICS CORPORATION
WPM SBA COMMUNICATIONS CORP. CLASS A
OKTA WHEATON PRECIOUS METALS CORP
KALA OKTA INC. CLASS A
CNX KALA PHARMACEUTICALS INC.
SE CNX RESOURCES CORPORATION
AMZN SEA ADS
AMD AMAZON.COM INC.
KRMD ADVANCED MICRO DEVICES INC.
SIGA REPRO MED SYSTEMS
SWCH SIGA TECHNOLOGIES INC.
LQDA SWITCH
PRNB LIQUIDIA CORPORATION
FTCH PRINCIPIA BIOPHARMA
ARAV FARFETCH LIMITED CLASS A
ALLO ARAVIVE
MRNA ALLOGENE THERAPEUTICS
MODERNA INC.
- Dave Nicoski
- Ross LaDuke
RGLD ROYAL GOLD INC.
NEM NEWMONT CORPORATION
ILMN ILLUMINA INC.
VRSN VERISIGN INC.
UNH UNITEDHEALTH GROUP INCORPORATED
TYL TYLER TECHNOLOGIES INC.
TSLA TESLA INC
TER TERADYNE INC.
SNPS SYNOPSYS INC.
SMG SCOTTS MIRACLE-GRO COMPANY CLASS A
NVDA NVIDIA CORPORATION
NPTN NEOPHOTONICS
NDAQ NASDAQ INC.
MPWR MONOLITHIC POWER SYSTEMS INC.
MOH MOLINA HEALTHCARE INC.
MKTX MARKETAXESS HOLDINGS INC.
LLNW LIMELIGHT NETWORKS
INTC INTEL CORPORATION
HUM HUMANA INC.
EBAY EBAY INC.
DRNA DICERNA PHARMACEUTICALS
CNC CENTENE CORPORATION
CHTR CHARTER COMMUNICATIONS INC. CLASS A
ANSS ANSYS INC.
AMED AMEDISYS INC.
ABX. BARRICK GOLD CORPORATION
NFLX NETFLIX INC.
MRVL MARVELL TECHNOLOGY GROUP LTD.
FIVN FIVE9 INC.
CCO. CAMECO CORPORATION
AEM. AGNICO EAGLE MINES LIMITED
EA ELECTRONIC ARTS INC.
ENTG ENTEGRIS INC.
LSCC LATTICE SEMICONDUCTOR CORPORATION
4MG MATCH GROUP INC.
SAM BOSTON BEER COMPANY INC. CLASS A
TDC TERADATA CORPORATION
ZNGA ZYNGA INC. CLASS A
INSG INSEEGO CORP
SPGI S&P GLOBAL INC.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
MSFT MICROSOFT CORPORATION
ZS ZSCALER INC.
SWCH SWITCH
DOCU DOCUSIGN INC.
PING PING IDENTITY HOLDING
FVRR FIVERR INTERNATIONAL
CGEN COMPUGEN LTD.
- MarketLine Department
AdheraTherapeutics - Mergers & Acquisitions (M&A), Partnerships & Alli...
Summary Marketline's AdheraTherapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by AdheraTherapeutics since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
NUE NUCOR CORPORATION
XEC CIMAREX ENERGY CO.
WOR WORTHINGTON INDUSTRIES INC.
SUPN SUPERNUS PHARMACEUTICALS INC.
ROK ROCKWELL AUTOMATION INC.
RAVN RAVEN INDUSTRIES INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRLB PROTO LABS INC.
PII POLARIS INC.
MYL VIATRIS INC.
MRO MARATHON OIL CORPORATION
CMC JPMORGAN CHASE & CO.
HON HONEYWELL INTERNATIONAL INC.
HII HUNTINGTON INGALLS INDUSTRIES INC.
GD GENERAL DYNAMICS CORPORATION
EMR EMERSON ELECTRIC CO.
DRNA DICERNA PHARMACEUTICALS
CR CRANE CO.
CAKE CHEESECAKE FACTORY INCORPORATED
BRSS GLOBAL BRASS AND COPPER HOLDINGS INC.
ATI ALLEGHENY TECHNOLOGIES INCORPORATED
ASH ASHLAND GLOBAL HOLDINGS INC.
ALXN ALEXION PHARMACEUTICALS INC.
ALB ALBEMARLE CORPORATION
TEX TEREX CORPORATION
BC BRUNSWICK CORPORATION
BIO BIO-RAD LABORATORIES INC. CLASS A
CMG CHIPOTLE MEXICAN GRILL INC.
HP HELMERICH & PAYNE INC.
LMT LOCKHEED MARTIN CORPORATION
MRTN MARTEN TRANSPORT LTD.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
X UNITED STATES STEEL CORPORATION
NTLA INTELLIA THERAPEUTICS INC.
APTV APTIV PLC
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
Dicerna Reports First Quarter 2018 Financial and Operating Results and...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the first quarter ended March 31, 2018. “Dicerna is off to a strong start in 2018 with the achievement of a number of important milestones for our lead GalXC™ program, DCR-PHXC, currently in development for primary hyperoxaluria,” said Douglas M. Fambrough, Ph.D., president and chief executive office...
Dicerna to Report First Quarter 2018 Financial Results and Host Confer...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on Monday, May 14, 2018. Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and will be avail...
Dicerna Pharmaceuticals Announces Settlement of All Litigation with Al...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has resolved all litigation with Alnylam Pharmaceuticals, Inc. The settlement allows Dicerna to advance all of its key and planned pipeline programs while maintaining a strong balance sheet. “With today’s announcement of a settlement with Alnylam, we are now able to focus the entirety of our resources on the advancemen...
Dicerna to Present at the H.C. Wainwright Global Life Sciences Confere...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate update at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 10:15 a.m. CET. The conference will be held April 8-10, 2018 at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. A live webcast of the presentation c...
Dicerna to Present at the B. Riley FBR Inaugural China Healthcare Inve...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will provide a corporate overview at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium on Friday, March 16, 2018 at 4:30 p.m. local time. The conference will be held March 16-17, 2018 at The InterContinental Hotel Hangzhou. About Dicerna...
Dicerna Reports Fourth Quarter and Year End 2017 Financial and Operati...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the fourth quarter and full-year ended December 31, 2017. “2017 was a transformative year for Dicerna, as we successfully transitioned to a clinical stage company advancing our growing pipeline of GalXC™-based RNAi therapeutics, and signed our first GalXC platform collaboration agreement with Boehring...
Dicerna to Present at the Cowen and Company 38th Annual Health Care Co...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference on Monday, March 12, 2018 at 2:50 p.m. ET. The conference will be held March 12-14, 2018 at The Boston Marriott Copley Place. A live webcast of the presentation can be accessed on the Investo...
Dicerna to Report Fourth Quarter and Full Year 2017 Financial Results ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its fourth quarter and full year 2017 financial results after market close on Thursday, March 8, 2018. Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live via the Internet and ...
Dicerna to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in two investor conferences. SunTrust Rare Disease Day - Dr. Fambrough will participate in the SunTrust Robinson Humphrey 2018 Orphan Drug Day on Tuesday, February 13, 2018, at the JW Marriott Essex House in New York. L...
Dicerna to Present at Noble Capital Markets’ NobleCon14
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (Nasdaq:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference on Tuesday, January 30, 2018 at 11:30 a.m. ET. The conference will be held at the W Hotel in Fort Lauderdale, Florida. A live webcast of the presentation can be accessed on t...
Dicerna Announces Pricing of Follow-On Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (“Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the pricing of its underwritten registered public offering of 5,714,286 shares of its common stock at a price to the public of $7.00 per share. Dicerna also granted the underwriters a 30-day option to purchase up to 857,143 additional shares of common stock. Closing of the offering is expected to occur on or about December 18, 2017,...
Dicerna Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (“Dicerna” or the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today the commencement of a proposed underwritten public offering of shares of its common stock (“Common Stock”). The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Dic...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.